ReviewCureus2026
Association Between Gastroesophageal Reflux Disease and Frequency of Asthma Exacerbations: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is common in patients with asthma; however, its role in asthma exacerbations remains unclear due to inconsistent study findings. This systematic review and meta-analysis aimed to synthesize the available evidence on the relationship between GERD and asthma exacerbations through two complementary objectives: (1) to assess the association between the presence of GERD and the frequency of asthma exacerbation in observational studies, and (2) to evaluate the effect of anti-reflux therapy (primarily proton pump inhibitors) on asthma exacerbations in randomized controlled trials (RCTs). Five research databases were searched up to December 2025 for RCTs and observational studies. A total of 10 studies were included, comprising six RCTs and four observational studies. Risk of bias was assessed using Risk of Bias 2 (ROB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tools. A random-effects model was used to pool the data, and heterogeneity was explored through subgroup analyses. The overall pooled effect was not statistically significant (standardized mean difference (SMD) = -0.12, 95% confidence interval (CI): -0.41 to 0.16, p = 0.323), with high heterogeneity (I² = 77.87%). Subgroup analysis revealed a statistically significant difference based on symptom status. Anti-reflux therapy significantly reduced asthma exacerbations in patients with symptomatic GERD (SMD = -0.41, 95% CI: -0.72 to -0.10), whereas no significant benefit was observed in patients without GERD symptoms. No significant differences were found across subgroups based on study design or diagnostic method. Overall, no significant association between GERD and asthma exacerbations was identified. However, symptom status appeared to act as a clinically significant effect modifier. Anti-reflux therapy may benefit asthmatic patients with symptomatic GERD, but empirical treatment of all asthmatic patients with evidence of reflux is not supported. These findings favor a symptom-driven treatment approach rather than routine empirical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.